AKRO - Akero Corp Total Debt to Capital
The price trend visualization on GURU.Markets for Akero Therapeutics (AKRO), where the debt-to-equity ratio is 0.00, is accompanied by the implementation of robotic laboratories and data analysis systems. The business relies on the success of Efruxifermin and cost control, striving to protect its intellectual property. Akero Therapeutics (AKRO) minimizes risks by developing unique treatments for mass liver pathologies, which provides access to a colossal market.
%20-%20All%20Debt%20to%20Shareholders'%20Equity%20Ratio&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261031&filename=GURU_Markets_-_AKRO_-_Akero-Therapeutics_-_All-Debt-to-Shareholders-Equity-Ratio "AKRO (Akero Therapeutics) Total Debt to Capital history from 07/04/2022 to 12/20/2025 | 👁️GURU.Markets👁️")
Analytical breakdowns for Akero Therapeutics
This ratio determines the degree of business dependence on borrowed funds by comparing total liabilities to net asset value to assess financial stability. An analysis of the leverage ratio—total debt to equity—reveals how effectively Akero Therapeutics (AKRO) finances the development of breakthrough liver cirrhosis drugs, balancing debt load against investments in clinical growth.